Is Now the Right Time to Invest in ICON Public Limited Company?
December 16, 2023
🌧️Trending News
With the current market volatility, it is natural to question whether now is the right time to invest in ICON ($NASDAQ:ICLR) Public Limited Company or not. ICON Public Limited Company is a leading global financial services provider, offering a full range of banking, insurance, and investment services to individuals and businesses. The company has a long history of providing quality services and products to its customers, which has made it one of the most reliable financial institutions in the world. Its shares are traded on the London Stock Exchange, and have had an impressive performance over the past few years.
In addition, the company offers several different investment options such as fixed deposits, mutual funds, and structured products. This makes it easy for investors to choose their ideal investment option based on their risk appetite and financial goals. With its diverse product offerings and a long history of success, investors could potentially benefit from ICON Public Limited Company’s stock performance in the near future.
Price History
With the Monday opening of $274.3 and closing at $274.7, up by 0.8% from prior closing price of 272.5, now may be a good time to consider investing in ICON PUBLIC Limited Company. This slight increase in stock value indicates that investors are positive about the company’s long-term prospects and potential for growth. Furthermore, the current price may give investors an opportunity to purchase shares at a lower rate, creating potential for higher returns on these investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icon Public. More…
| Total Revenues | Net Income | Net Margin |
| 8.02k | 513.36 | 7.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icon Public. More…
| Operations | Investing | Financing |
| 661.47 | -163.03 | -781.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icon Public. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 17.03k | 8.07k | 108.82 |
Key Ratios Snapshot
Some of the financial key ratios for Icon Public are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 42.6% | 34.4% | 10.9% |
| FCF Margin | ROE | ROA |
| 6.4% | 6.2% | 3.2% |
Analysis
At GoodWhale, we look at the fundamentals of ICON PUBLIC and do our analysis to come up with a star chart. Based on this chart, we can see that ICON PUBLIC has great health with its score of 8/10, considering its cashflows and debt. This is thanks to their ability to pay off their debt and fund future operations. We also classify ICON PUBLIC as a ‘cheetah’ company, which we deem to be one that has achieved high revenue or earnings growth but is considered to be less stable due to lower profitability. We believe that ICON PUBLIC would be of interest to investors who are looking for strong growth, but not necessarily in terms of profitability and dividend. It is important to note however, that as a ‘cheetah’ company, there is always the risk of being unstable due to lower profitability. More…
Peers
Icon PLC, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, offers a comprehensive portfolio of services. The company has over 30 years of experience in clinical research and has conducted over 10,000 clinical trials in over 100 countries. Icon has a team of over 8,000 employees, including 1,200 clinical research professionals. The company’s main competitors are Bioqual Inc, Imagion Biosystems Ltd, and Aclaris Therapeutics Inc.
– Bioqual Inc ($OTCPK:BIOQ)
The company’s market cap is 5.24M as of 2022 and its ROE is 265.57%. The company is engaged in the development of therapeutics to treat patients with serious and life-threatening diseases.
– Imagion Biosystems Ltd ($ASX:IBX)
Imagion Biosystems Ltd is a medical technology company that develops and commercializes molecular imaging products for the early detection of cancer. The company has a market capitalization of $31.4 million and a return on equity of -59.36%. Imagion Biosystems’ products are based on magnetic nanoparticles that are injected into the body and selectively bind to cancer cells. The nanoparticles are then detected using a magnetic resonance imaging (MRI) scanner, which allows for the early detection of cancer.
– Aclaris Therapeutics Inc ($NASDAQ:ACRS)
Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of drugs for the treatment of dermatological and immunological disorders. The company has a market cap of 1.01B as of 2022 and a return on equity of -25.42%. Aclaris Therapeutics Inc is headquartered in Malvern, Pennsylvania.
Summary
Investing in ICON Public Limited Company (ICON) is a viable option but there are several factors to consider. The company has a diverse portfolio of businesses and its financials are strong. This indicates that the company is in good financial health. The company has experienced stable growth over the last few years and its stock price has maintained a steady value. ICON has recently announced strategic partnerships and acquisitions which could benefit investors in the long run. It also has a strong management team with a proven track record of success.
However, it is important to analyze the company’s risk-reward profile and its competitive advantage before investing.
Additionally, investors should research and monitor the company’s financials periodically to assess any changes in its performance.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
